ISRCTN01982076 https://doi.org/10.1186/ISRCTN01982076

RheumAFooT (Rheumatoid Arthritis Foot Trial)

Submission date 14/08/2003	**Recruitment status** No longer recruiting	[X] Prospectively registered [_] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 18/08/2003	**Overall study status** Completed	
Last Edited 22/11/2007	**Condition category** Musculoskeletal Diseases	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr James Woodburn

Contact details
Academic Unit of Musculoskeletal Disease
School of Medicine
University of Leeds
Leeds
United Kingdom
LS2 9NZ
+44 (0)113 343 4938
j.woodburn@leeds.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
G108/397

Study information

Scientific Title

Acronym
RheumAFooT

Study objectives
The aim of this trial is to compare podiatry with no podiatry footcare in rheumatoid arthritis (RA) patients with painful and disabling foot symptoms.

The objectives are:
Primary objective: To compare foot health status (activities, impairment, participation and shoe) between active and control groups using the Leeds Foot Impact Scale.
Secondary objective 1: To compare foot function (spatial and temporal gait parameters) between the two groups using instrumented gait analysis.
Secondary objective 2: To test whether the effect of podiatry, as measured by Leeds Foot Impact Scale, is correlated with patient sex, disease duration and degree of initial foot health status.
Secondary objective 3: To determine the cost effectiveness of podiatry care for RA related foot problems.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration.

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Rheumatoid arthritis

Interventions
Active treatment arm: 12 months podiatry care
Control treatment arm: 12 months

Intervention Type

Other

Phase
Not Specified

Primary outcome measure
Primary outcome: change in Leeds Foot Impact Scale score between baseline and 12 months.

Secondary outcome measures
Disease activity score, health assessment questionnaire and walking speed were also recorded.

Overall study start date
01/10/2003

Completion date
30/09/2005

Eligibility

Key inclusion criteria
Patients will be suitable for inclusion if they have a definite diagnosis of RA (satisfying the 1987 American Rheumatism Association revised criteria for RA), are between 18-80 years of age and can read and write English. Patients must also have a current history of foot impairment as determined by standard history and clinical examination techniques and a Leeds Foot Impact Scale score of ≥15 points. Patients must also have stable drug management in the 3 months prior to recruitment including Disease Modifying Anti-Rheumatic Drugs, Non-Steroidal Anti-Inflammatory Drugs and oral corticosteroids.

Participant type(s)
Patient

Age group
Adult

Lower age limit
18 Years

Upper age limit
80 Years

Sex
Both

Target number of participants
34

Key exclusion criteria
Patients will be excluded if they have foot problems related to and require treatment under the appropriate medical specialty such as diabetes and peripheral vascular disease. Patients will be excluded if they have severe complications of their RA resulting in active or high risk of

developing foot ulceration. On medical consultation, any patient with foot problems, such as ulceration and infection, likely to complicate systematic treatment with biologic and other immunosuppressant therapy (Infliximab, Etanercept, Anakinra, Cyclophosphamide, Cyclosporin, Azathioprine and any new, including trial, biologic - even if placebo) will be excluded. Those patients who have received podiatry treatment at Leeds General Infirmary Foot Health Department in the last 3 months will also be excluded.

Date of first enrolment
01/10/2003

Date of final enrolment
30/09/2005

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
Academic Unit of Musculoskeletal Disease
Leeds
United Kingdom
LS2 9NZ

Sponsor information

Organisation
Medical Research Council (UK)

Sponsor details
20 Park Crescent
London
United Kingdom
W1B 1AL
+44 (0)20 7670 5259
clinical.trial@headoffice.mrc.ac.uk

Sponsor type
Government

Funder(s)

Funder type
Government

Funder Name
Medical Research Council (UK)

Alternative Name(s)
Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	06/11/2007		Yes	No